BGM Group Ltd.: stock overview

BGMNASDAQHealthcare · Pharmaceutical Preparations

Price

$7.88

November 13, 2026

DCF calculator

What Ploutos Investor adds for BGM

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 8 fiscal years, from FY2018
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price was recently adjusted for a split or a spin-off that the company's last filing does not include yet. Market value, P/E, yields and the other figures measured against the price would mix the new shares with the old figures, so we leave them out until the next filing.
  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.

In short

BGM had revenue of $38M in the fiscal year to September 30, 2025 and a net loss of $20M. Revenue fell by 5.4% a year on average over the last 5 years. It holds more cash than debt, by $8.2M. It pays no dividend.

From its SEC filings (latest fiscal year to September 30, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
–
201M shares
P/E
–
Revenue, fiscal year
$38M
-5.4% a year over 5 years
Net margin
-52.6%
above 20% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

FY2023–FY2025 fiscal years

-9.7% a year over 2 years

  • FY2025Sep 30, 202520-F
    Revenue$38M
  • FY2024Sep 30, 202420-F
    Revenue$25M
  • FY2023Sep 30, 202320-F
    Revenue$46M

Fiscal years in figures

BGM's revenue, profit, cash flow and dividend with each year-end price, from FY2018 to FY2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Sorry, we do not have enough data

for the “Valuation” group

Profitability

Gross margin 
16.6%
Operating margin 
-33.2%
Net margin 3-year median: -16.7%
-52.6%
ROIC 
-2.5%
ROIC, 5-year average 
-0.4%
ROE, fiscal year 
-5.1%

Growth

Revenue, yearly change 
+51.1%
EPS, yearly change 
–
FCF, yearly change 
-1,395.3%
Revenue, average a year 
-5.4%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$9.8M
Total debt 
$1.9M
Of which operating leases 
$320.3K
Net cash 
$8.2M
Net debt / EBITDA 
–
Interest cover 
–
Current ratio 
–

Balance sheet of September 30, 2025.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+2,676.2%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 28).

Gross margin

16.6%

Above 15% of the 141 companies in its industry, and 17% of all.

Operating margin

-33.2%

Above 27% of the 285 companies in its industry, and 10% of all.

Net margin

-52.6%

Above 20% of the 302 companies in its industry, and 6% of all.

Revenue growth

51.1%

Above 86% of the 292 companies in its industry, and 94% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
BGM Group Ltd.
CIK
1779578
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
September 30
Latest annual report
September 30, 2025
Reporting currency
USD
Shares
201M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do BGM's filings show?

These are BGM's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about BGM

Didn't find what you were looking for?

Ask us
How much revenue does BGM have?

BGM had revenue of $38M in the fiscal year to September 30, 2025. Over the last 5 years it changed by -5.4% a year on average.

Does BGM pay a dividend?

No. BGM paid no regular dividend over the last 12 months.

Where do the figures come from?

From BGM Group Ltd.'s SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.